申请人:MERCK SHARP & DOHME LTD.
公开号:EP0307140A1
公开(公告)日:1989-03-15
Oxadiazoles represented by structural formula I:
or a salt or prodrug thereof; wherein
one of X, Y or Z is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds);
R² represents a substituent of low lipophilicity;
the broken line represents an optional chemical bond; and
the substituents R³ and R⁴ may be present at any position, including the point of attachment to the oxadiazole ring, and R³ represents halo, C₁₋₄ alkoxy, carboxy, -NR⁷R⁸, C₂₋₄ alkyl, C₁₋₄ alkyl substituted with hydroxy or C₁₋₄ alkoxy, or methyl or hydroxy in the 3-, 4- or 5-position; and R⁴ represents hydrogen, halo, C₁₋₄ alkoxy, hydroxy, carboxy, -NR⁷R⁸, C₁₋₄ alkyl, or C₁₋₄ alkyl substituted with hydroxy or C₁₋₄ alkoxy; or R³ and R⁴ together represent carbonyl; and
R⁷ and R⁸ independently represent hydrogen or C₁₋₂ alkyl
are potent muscarinic agonists with good CNS penetrability, and are therefore useful in the treatment of neurological and mental illnesses; the compounds are also of benefit in the treatment of severe painful conditions. Processes for preparing these compounds are described, as also are pharmaceutical compositions containing them.
结构式 I 所代表的噁二唑
或其盐或原药; 其中
X、Y 或 Z 中的一个是氧原子,另外两个是氮原子,圆点代表芳香性(两个双键);
R² 代表亲脂性低的取代基;
折线代表可选的化学键;以及
取代基 R³ 和 R⁴ 可存在于任何位置,包括与噁二唑环的连接点,R³ 代表卤素、C₁₋₄ 烷氧基羧基、-NR⁷R⁸、C₂₋₄烷基、被羟基或 C₁₋₄ 烷氧基取代的 C₁₋₄ 烷基或位于 3、4 或 5 位的甲基或羟基;和 R⁴ 代表氢、卤素、C₁₋₄ 烷氧基、羟基、羧基、-NR⁷R⁸、C₁₋₄ 烷基、或被羟基或 C₁₋₄ 烷氧基取代的 C₁₋₄ 烷基;或 R³ 和 R⁴ 共同代表羰基;和
R⁷ 和 R⁸ 各自代表氢或 C₁₋₂ 烷基
是强效毒蕈碱激动剂,具有良好的中枢神经系统穿透性,因此可用于治疗神经和精神疾病;这些化合物还可用于治疗剧烈疼痛。本文介绍了制备这些化合物的工艺,以及含有这些化合物的药物组合物。